Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure

The legacy context of general health and science information has long served as a foundation for public understanding of medical conditions and treatment options. Within this broad framework, discussions of bone health, pharmaceutical interventions, and potential adverse effects have been standard topics. The transition from this general health perspective to a more specific occupational exposure concern requires a shift in focus from population-level awareness to individual risk factors in particular environments. In the domain of mass production, workers may encounter materials and substances that differ from typical consumer exposures. The scientific evidence connecting Fosamax, a bisphosphonate medication, to osteonecrosis of the jaw represents a specific area where general health knowledge intersects with occupational considerations. While the general public primarily encounters this medication through prescription for osteoporosis, those involved in manufacturing or handling such compounds face distinct exposure patterns. This pivot from general health information to occupational exposure concern acknowledges that production environments can create unique risk profiles.

Bridging Clinical Evidence to Workplace Risk

The bridge concept here involves recognizing that the same scientific understanding of causation between Fosamax and osteonecrosis of the jaw, developed in clinical settings, must be applied to workplace contexts where exposure routes, durations, and intensities may differ substantially from therapeutic use. This transition sets the stage for examining how mass production settings might require specialized attention to these established health risks. Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves inhibiting bone resorption, thereby increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Osteonecrosis of the Jaw: Clinical Presentation and Risk Factors

A serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for weeks to months, often accompanied by pain, swelling, infection, and delayed healing after dental procedures. Diagnosis is primarily clinical, based on visual examination and history, and may be supported by imaging to rule out other pathologies. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Animal Evidence

The mechanistic pathways linking Fosamax to ONJ are rooted in its pharmacological action. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover. In the jawbone, which undergoes frequent remodeling due to mechanical stress from chewing and dental procedures, this suppression may impair the ability to repair microdamage and maintain bone health. Multiscale characterization of jawbone in animal models treated with bisphosphonates has provided insights into these effects. Studies using estrogen-deficient rats treated with alendronate have examined changes in tissue mineral density distribution, nanoindentation properties, and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077/). These investigations aim to understand jawbone-specific responses to bisphosphonate therapy and their role in ONJ development (https://pubmed.ncbi.nlm.nih.gov/40345077/). The reduced bone turnover may lead to accumulation of microdamage and increased susceptibility to infection or trauma, particularly after dental procedures.

Timeline of Exposure and Onset of Harm

Regarding the timeline between exposure and documented harm, the time to onset of ONJ symptoms can vary widely. According to labeling information, the time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ is more commonly reported after longer-term use, and the risk may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as bone pain were similar in the Fosamax and placebo groups, but ONJ specifically has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experienced relief of symptoms after stopping the drug, though a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Causation Considerations

The adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's prescribing information. The label includes a specific section (5.4) titled 'Osteonecrosis of the Jaw' that describes the condition, its association with dental procedures, and known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients, causation considerations involve evaluating the temporal relationship between Fosamax exposure and ONJ onset, the presence of other risk factors such as dental procedures or cancer therapies, and the exclusion of other causes. The label acknowledges that ONJ can occur spontaneously but is generally associated with dental procedures and local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may be higher in patients with cancer receiving concomitant therapies, but ONJ has also been reported in osteoporosis patients using bisphosphonates. The multiscale characterization of jawbone in animal studies provides a biological basis for understanding how bisphosphonates may contribute to ONJ, though direct extrapolation to humans requires further research (https://pubmed.ncbi.nlm.nih.gov/40345077/). In summary, scientific evidence supports a causal association between Fosamax and osteonecrosis of the jaw, with mechanistic plausibility related to suppressed bone turnover, a variable but documented timeline, and recognized risk factors. Warnings in the prescribing information inform clinicians and patients, though individual risk assessment remains important.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence connecting Fosamax to osteonecrosis of the jaw?

Scientific evidence includes clinical reports, animal studies, and mechanistic understanding. Fosamax (alendronate) suppresses bone turnover, which can impair jawbone repair. Animal studies show changes in jawbone properties (https://pubmed.ncbi.nlm.nih.gov/40345077/). Clinical data indicate ONJ occurs in patients taking bisphosphonates, with onset ranging from days to months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing osteonecrosis of the jaw from Fosamax?

Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for Fosamax to cause osteonecrosis of the jaw?

Onset can vary from one day to several months after starting the drug, but it is more common with longer-term use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.